報價延遲最少15分鐘:2025/12/26 17:06 EST
盤後時段
|
||||
|
1.1399 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.13
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.34/0.67
|
|
企業價值
100.89M
|
| 資產負債 |
|
每股賬面淨值
0.53
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks,and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications forapproved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients. |
